Description
MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO THE CONTRACT.
Base award description: NEW AWARD FOR RITUXIMAB WITH PFIZER INC. BASE YEAR ORDERING PERIOD IS SEPTEMBER 15, 2025 TO SEPTEMBER 14, 2026 WITH FOUR ONE-YEAR OPTIONS.
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2025-04-29+$0= $0
- Mod P000012025-12-02+$0= $0
- Mod P000022026-01-12+$0= $0
- Mod P000032026-07-16+$0= $0
- Mod P000042026-09-02+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2025-04-29 | +$0 | $0 | NEW AWARD FOR RITUXIMAB WITH PFIZER INC. BASE YEAR ORDERING PERIOD IS SEPTEMBER 15, 2025 TO SEPTEMBER 14, 2026… |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2025-12-02 | +$0 | $0 | INCORPORATION OF 2026 FEDERAL CEILING PRICE INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICE REMAINS UNCHANG… |
| Mod P00002· ADD SUBCONTRACTING PLAN | 2026-01-12 | +$0 | $0 | INCORPORATION OF 2026 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79725D0032 - RITUXIMAB-PVVR (RUXIENC… |
| Mod P00003· EXERCISE AN OPTION | 2026-07-16 | +$0 | $0 | EXERCISE OPTION YEAR 1, EFFECTIVE SEPT. 15, 2026 - SEPT. 14, 2027, FOR RITUXIMAB-PVVR (RUXIENCE) WITH PFIZER I… |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-09-02 | +$0 | $0 | MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI MHBQULRMEEJ5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79725D0030 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36C77024P0393 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $243,101 | FY2024 |
| 36F79724D0130 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2024 |
| 36C25024F0047 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $215,205 | FY2024 |
| 36E79723A0023 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79720D0067 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2020 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79725D0032_3600 · retrieved 2026-09-26.